Proof-of-concept was provided in a phase 2a trial of a de novo-designed TNIK inhibitor in idiopathic pulmonary fibrosis, in which safety, tolerability, and pharmacodynamic target engagement were demonstrated, with a trend toward reduced functional decline. This evidence concerns the gene TNIK and pulmonary fibrosis.